Our Pipeline
OUR PIPELINE
Dragonfly's novel cytokines and "TriNKET" NK cell engagers can both kill cancers and other disease targets directly, and improve the outcomes of other immunotherapy approaches like T-cell therapies.
Dragonfly’s pipeline is robust and continues to grow both internally and with BMS, Merck, and AbbVie
PRECLINICAL
IND FILING
PHASE I
PHASE II
DF1001 HER2-Targeting TriNKET
DF9001 (Solid Tumor) TriNKET
DF7001 (Solid Tumor) TriNKET
DF6200 (Oncology) Cytokine
DF5300 (Immunology) TriNKET
Dragonfly 10+ Preclinical TriNKETs
DF6002 (BMS-licensed) IL-12 Cytokine
DF2001 (BMS-licensed) Heme TriNKET
DF3001 (BMS-licensed) Heme TriNKET
DF4001 (BMS-licensed) Heme TriNKET
DF5008 (BMS-licensed) Heme TriNKET
DF2200 (BMS-licensed) Heme TriNKET
DF8000 (Merck-licensed) TriNKET
DF8100 (Merck-licensed) TriNKET
DF4100 (AbbVie-licensed) TriNKET
Dragonfly 6+ Partnered TriNKETs
